What are the possible side effects of using Vigabatrin/vigabatrin?

Vigabatrin/vigabatrin is an irreversible GABA transaminase inhibitor, mainly used to treat drug-resistant epilepsy, especially infantile spasms (West syndrome) and refractory focal epilepsy. It exerts anti-epileptic effects by inhibiting the breakdown of GABA (gamma-aminobutyric acid) and increasing GABA levels in the brain. However, due to its special mechanism of action, Vigabatrin may cause a series of side effects, the most serious of which is visual field loss, so the patient's visual health needs to be strictly monitored during use.

Visual field defect (Vigabatrin-Associated Visual Field Defect (VAVFD)) is the most common and irreversible side effect. Research shows that about 30-50% of patients who take Vigabatrin for a long time may experience varying degrees of bilateral peripheral visual field narrowing, and in severe cases, it may even lead to a tube-shaped visual field. The mechanism of optic nerve damage is not fully understood but may be related to drug-induced neurotoxicity. Due to the irreversible nature of this side effect, patients are required to have a baseline vision examination before using Vigabatrin and undergo regular ophthalmic monitoring during treatment.

In addition to vision problems, Vigabatrin may cause neurological side effects, including drowsiness, dizziness, ataxia (unsteady gait), depression, and mood changes. Some patients may experience cognitive decline, especially with long-term use, which is particularly significant in pediatric patients. In addition, a small number of patients may experience mental abnormalities, such as hallucinations, agitation, aggressive behavior, etc., and should be used with caution especially in patients with combined mental illnesses.

Overall, Vigabatrin, as an important drug in the treatment of drug-resistant epilepsy, has good efficacy, but its potential side effects cannot be ignored, especially the problem of visual field defects. In clinical application, doctors need to weigh its efficacy and risks, formulate appropriate treatment plans based on individual patient conditions, and conduct regular monitoring to ensure safety.

Reference materials:https://www.sabril.net/